McArdle disease: What do neurologists need to know?

Nature Clinical Practice Neurology

Volumn 4, Issue 10, 2008, Pages 568-577

  Lucia, Alejandro ^a   Nogales Gadea, Gisela ^b   Pérez, Margarita ^a   Martín, Miguel A ^b   Andreu, Anton L ^b   Arenas, Joaquín ^b  

^a UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; DANTROLENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENTAMICIN; GLUCOSE; PLACEBO; PTC 124;

AEROBIC EXERCISE; ANAMNESIS; CARBOHYDRATE DIET; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC TEST; EXERCISE TOLERANCE; FATIGUE; GLUCOSE UTILIZATION; GLYCOGEN STORAGE DISEASE TYPE 5; GLYCOGENOLYSIS; HUMAN; LOW DRUG DOSE; MEDICAL SPECIALIST; MOLECULAR GENETICS; MUSCLE BIOPSY; MUSCLE CONTRACTION; MUSCLE CONTRACTURE; MYOGLOBINURIA; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS;

GLYCOGEN STORAGE DISEASE TYPE V; HUMANS; NEUROLOGY;

EID: 54049125345     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0913     Document Type: Review

References (70)

1. Haller RG (2000) Treatment of McArdle disease. Arch Neurol 57 923-924
2. McArdle B (1951) Myopathy due to a defect in muscle glycogen breakdown. Clin Sci 10: 13-33
3. Andreu AL et al. (2007) McArdle disease: Molecular genetic update. Acta Myol 26: 53-57
4. DiMauro S (2007) Muscle glycogenoses: An overview. Acta Myol 26 35-41
5. Isackson PJ et al. (2005) A novel mutation in the PYGM gene in a family with pseudo-dominant transmission of McArdle disease. Mol Genet Metab 85: 239-242
6. Tsujino, S et al. (11993) Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle's disease). N Engl J Med 329: 241-245
7. DiMauro S et al. (2002) Myophosphorylase deficiency (glycogenosis type V; McArdle disease). Curr Mol Med 2: 189-196
8. Vissing J and Haller RG (2003) The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med 349 2503-2509
9. Zange J et al. (2003) Breakdown of adenine nucleotide pool in fatiguing skeletal muscle in McArdle's disease: A noninvasive 31P-MRS and EMG study. Muscle Nerve 27: 728-736
10. Lewis SF and Haller RG (11986) The pathophysiology of McArdle's disease: clues to regulation in exercise and fatigue. J Appl Physiol 61 391-401
11. +-ATPase in McArdle disease. Neurology 50: 37-40
12. Martinuzzi A et al. (2003) Phenotype modulators in myophosphorylase deficiency. Ann Nueurol 53: 497-502
13. Rubio JC et al. (2007) Genotype modulators of clinical severity in McArdle disease. Neurosci Lett 422: 217-222
14. Maté-Muñoz JL et al. (2007) Favorable responses to acute and chronic exercise in McArdle patients. Clin J Sport Med 117: 297-303
15. Paradas C et al. (2005) Variable presentation of the clinical phenotype of McArdle's disease in a kindred harbouring a novel compound genotype in the muscle glycogen phosphorylase gene. Neurosci Lett 31: 28-31
16. Voduc N et al. (2004) McArdle's disease presenting as unexplained dyspnea in a young woman. Can Respir J 11: 163-167
17. Williams AG et al. (2000) The ACE gene and muscle performance. Nature 403: 614
18. Gómez-Gallego F et al. (2008) The I allele of the ACE gene is associated with improved exercise capacity in women with McArdle disease. Br J Sports Med 42: 134-140
19. Tsujino S et al. (1995) Double trouble: Combined myophosphorylase and AMP deaminase deficiency in a child homozygous for nonsense mutations at both loci. Neuromuscul Disord 15: 263-266
20. Rubio JC et al. (2008) AMPD1 genotypes and exercise capacity in McArdle patients. Int J Sports Med 29: 331-335
21. Pérez M et al. (2007) Exercise capacity in a child with McArdle disease. J. Child Neurol 22: 880-882
22. DiMauro S and Hartlage PL (1978) Fatal infantile form of muscle phosphorylase deficiency. Neurology 28: 1124-1129
23. Pérez M et al. (2006) Exercise capacity in a 78 year old patient with McArdle's disease: It is never too late to start exercising. Br J Sports Med 40: 725-726
24. DiMauro S and Tsujino S (1995) Nonlysosomal glycogenoses. In Myology 1554-1556 (Eds Engel AG and Franzini-Armstrong C) New York: McGraw-Hill
25. Jinnai K et al. (1993) Glycogenosis type V (McArdle's disease) with hyperuricemia: A case report and clinical investigation. Eur Neurol 33: 204-207
26. Mineo I et al. (1997) Myogenic hyperuricemia: A common pathophysiologic feature of glycogenosis types III, V, and VII. N Engl J Med 317: 75-80
27. Bollig G et al. (2005) McArdle's disease and anaesthesia: Case reports: Review of potential problems and association with malignant hyperthermia. Acta Anaesthesiol Scand 49: 1077-1083
28. Lorenzoni PJ et al. (2007) McArdle disease with rhabdomyolysis induced by rosuvastatin: Case report [Portuguese]. Arq Neuropsiquiatr 65: 834-837
29. Pearson C et al. (1961) A metabolic myopathy due to absence of muscle phosphorylase. Am J Med 30: 502-517
30. Haller RG and Vissing J (2002) Spontaneous' second wind' and glucose-induced second' second wind' in McArdle disease: Oxidative mechanisms. Arch Neurol 59: 1395-1402
31. Haller RG and Vissing J (2004) No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology 62: 82-86
32. Haller RG and Lewis SF (1991) Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency. N Engl J Med 324: 364-369
33. Vissing J and Haller RG (2003) A diagnostic cycle test for McArdle's disease. Ann Neurol 54: 539-542
34. Ørngreen MC et al. (2008) Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency? Neurology 70: 1872-1873
35. Vissing J et al. (2005) Effects of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency. Arch Neurol 62: 1440-1444
36. Deschauer M et al. (2005) Muscle carnitine palmitoyltransferase II deficiency: Clinical and molecular genetic features and diagnostic aspects. Arch Neurol 62: 37-41
37. Lindner A et al. (2001). Acute compartment syndrome after forearm ischemic work test in a patient with McArdle's disease. Neurology 56: 1779-1780
38. Kazemi-Esfarjani P et al. (2002) A nonischemic forearm exercise test for McArdle disease. Ann Neurol 52: 153-159
39. Bergström J (1975) Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest 35 609-616
40. Nogales-Gadea G et al. (2007) Molecular genetics of McArdle's disease. Curr Neurol Neurosci Rep 7: 84-92
41. Bruno C et al. (2006) McArdle disease: The mutation spectrum of PYGM in a large Italian cohort. Hum Mutat 27: 718
42. Lebo RV et al. (1984) High-resolution chromosome sorting and DNA spot-blot analysis assign McArdle's syndrome to chromosome II. Science 225: 57-59
43. Bartram C et al. (1993) McArdle's disease: A nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Hum Mol Genet 2: 1291-1293
44. Aquaron R et al. (2007) Molecular characterization of myophosphorylase deficiency (McArdle disease) in 34 patients from Southern France: IdentificatioA of 10 new mutations: absence of genotype-phenotype correlation. Neuromuscul Disord 17: 235-241
45. Deschauer M et al. (2007) Analysis of spectrum and frequencies of mutations in McArdle disease: Identification of 13 novel mutations. J Neurol 254: 797-802
46. Martin MA et al. (2000) Molecular heterogeneity of myophosphorylase deficiency (McArdle's disease): A genotype-phenotype correlation study. Ann Neurol 50: 574-581
47. Rubio JC et al. (2006) A proposed molecular diagnostic flowchart for myophosphorylase deficiency (McArdle disease) in blood samples from Spanish patients. Hum Mutat 28: 203-204
48. Tsujino S et al. (1994) Three new mutations in patients with myophosphorylase deficiency (McArdle disease). Am J Hum Genet 54: 44-52
49. Fernandez R et al. (2000) A novel missense mutation (W797R) in the myophosphorylase gene in Spanish patients with McArdle disease. Arch Neurol 57: 217-219
50. Bruno C et al. (1999). Molecular characterization of McArdle's disease in two large Finnish families. J Neurol Sci 165: 121-125
51. Fernandez-Cadenas I et al. (2003) Splicing mosaic of the myophosphorylase gene due to a silent mutation in McArdle disease. Neurology 61: 1432-1434
52. García-Consuegra I et al.: Novel mutations inpatients with McArdle disease by analysis of skeletal muscle mRNA. J Med Genet, in press
53. Pad G et al. (1999) Myophosphorylase gene transfer in McArdle's disease myoblasts in vitro. Neurology 53: 1352-1354
54. Howell JM et al. (2008) Adenovirus and adeno-associated virus-mediated delivery of human myophosphorylase cDNA and LacZ cDNA to muscle in the ovine model of McArdle's disease: Expression and re-expression of glycogen phosphorylase. Neuromuscul Disord 18 248-258
55. Nogales-Gadea G et al. (2008) Expression of the muscle glycogen phosphorylase, gene in patients with McArdle disease: The role of nonsense-mediated mRNA decay. Hum Mutat 29: 277-283
56. Welch EM et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447: 87-91
57. Schroers A et al. (2006). Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency Neurology 66: 285-286
58. Martinuzzi A et al. (2008) Randomized, placebo-controlled, double-blind pilot trial of ramilpril in McArdle's disease. Muscle Nerve 37: 350-357
59. Poels PJ et al. (1990) Dantrolene sodium does influence the second-wind phenomenon in McArdle's disease: Electrophysiollogical evidence during exercise in a double-blind placebo-controlled, cross-over study in 5 patients. J Neurol Sci 100: 108-112
60. Steele IC et al. (1996) A double blind, placebo controlled, cross over trial of D-ribose in McArdle disease. J Neurol Sci 136: 174-177
61. Vorgerd M et al. (2002) Creatine therapy in myophosphorylase deficiency (McArdle disease): A placebo-controlled crossover trial. Arch Neurol 57: 956-963
62. Vorgerd M et al. (2002) Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: Double-blind, placebo-controlled crossover study. Arch Neurol 59: 97-101
63. Andersen ST and Vissing J (2008) Carbohydrate-and protein-rich diets in McArdle disease: Effects on exercise capacity. J Neurol Neurosurg Psychiatry [doi:10.1136/jnnp.2008.146548]
64. MacLean D et al. (1998) Oral branched chain amino acids do not improve exercise capacity in McArdle's disease. Neurology 51 1456-1459
65. Andersen ST et al. (2008) Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol 65 786-789
66. Quinlivan R et al. Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V). Cochrane Database Systematic Reviews 2008, Issue 1. Art. No.: CD003458. doi:10.1002/ 14651858.CD003458.pub3
67. Jensen KE et al. (1990) Kinetics following high protein diet in McArdle's syndrome: A 31P magnetic resonance spectroscopy study. Acta Neurol Scand 81: 499-503
68. Slonim AE and Goans PJ (1985) Myopathy in McArdle's syndrome: improvement with a high-protein diet. New Engl J Med 312: 355-359
69. Kushner RF and Berman SA (1990) Are high protein diets effective in McArdle's disease? Arch Neurol 47: 383-384
70. Haller RG et al. (2006) Aerobic conditioning: An effective therapy in McArdle's disease. Ann Neurol 59: 922-928